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2375PREAMBLE
The American College of Cardiology (ACC) and the
American Heart Association (AHA) are committed to the
prevention and management of cardiovascular diseases
through professional education and research for clini-
cians, providers, and patients. Since 1980, the ACC and
AHA have shared a responsibility to translate scientiﬁc
evidence into clinical practice guidelines (CPGs) with
recommendations to standardize and improve cardio-
vascular health. These CPGs, based on systematic
methods to evaluate and classify evidence, provide a
cornerstone of quality cardiovascular care.
In response to published reports from the Institute of
Medicine (1,2) and the ACC/AHA’s mandate to evaluate
new knowledge and maintain relevance at the point of
care, the ACC/AHA Task Force on Practice Guidelines
(Task Force) began modifying its methodology. This
modernization effort is published in the 2012 Methodol-
ogy Summit Report (3) and 2014 perspective article (4).
The latter recounts the history of the collaboration,
changes over time, current policies, and planned initia-
tives to meet the needs of an evolving health-care envi-
ronment. Recommendations on value in proportion to
resource utilization will be incorporated as high-quality
comparative-effectiveness data become available (5).
The relationships between CPGs and data standards,
appropriate use criteria, and performance measures are
addressed elsewhere (4).
Intended Use—CPGs provide recommendations appli-
cable to patients with or at risk of developing cardiovas-
cular disease. The focus is on medical practice in the
United States, but CPGs developed in collaboration with
other organizations may have a broader target. Although
CPGs may be used to inform regulatory or payer decisions,
the intent is to improve quality of care and be aligned
with the patient’s best interest.
Evidence Review—Guideline writing committee (GWC)
members are charged with reviewing the literature;
weighing the strength and quality of evidence for or
against particular tests, treatments, or procedures; and
estimating expected health outcomes when data exist. In
analyzing the data and developing CPGs, the GWC uses
evidence-based methodologies developed by the Task
Force (6). A key component of the ACC/AHA CPG meth-
odology is the development of recommendations on the
basis of all available evidence. Literature searches focus
on randomized controlled trials (RCTs) but also include
registries, nonrandomized comparative and descriptive
studies, case series, cohort studies, systematic reviews,
and expert opinion. Only selected references are cited in
the CPG. To ensure that CPGs remain current, new data
are reviewed biannually by the GWCs and the Task Force
to determine if recommendations should be updated ormodiﬁed. In general, a target cycle of 5 years is planned
for full revision (1).
The Task Force recognizes the need for objective,
independent Evidence Review Committees (ERCs) to
address key clinical questions posed in the PICOTS
format (P¼population; I¼intervention; C¼comparator;
O¼outcome; T¼timing; S¼setting). The ERCs include
methodologists, epidemiologists, clinicians, and bio-
statisticians who systematically survey, abstract, and
assess the quality of the evidence base (3,4). Practical
considerations, including time and resource constraints,
limit the ERCs to addressing key clinical questions for
which the evidence relevant to the guideline topic lends
itself to systematic review and analysis when the sys-
tematic review could impact the sense or strength of
related recommendations. The GWC develops recom-
mendations on the basis of the systematic review and
denotes them with superscripted “SR” (i.e., SR) to
emphasize support derived from formal systematic
review.
Guideline-Directed Medical Therapy—Recognizing
advances in medical therapy across the spectrum of car-
diovascular diseases, the Task Force designated the
term “guideline-directed medical therapy” (GDMT) to
represent recommended medical therapy as deﬁned
mainly by Class I measures—generally a combination
of lifestyle modiﬁcation and drug- and device-based
therapeutics. As medical science advances, GDMT
evolves, and hence GDMT is preferred to “optimal medi-
cal therapy.” For GDMT and all other recommended
drug treatment regimens, the reader should conﬁrm
the dosage with product insert material and carefully
evaluate for contraindications and possible drug in-
teractions. Recommendations are limited to treatments,
drugs, and devices approved for clinical use in the United
States.
Class of Recommendation and Level of Evidence—
Once recommendations are written, the Class of Recom-
mendation (COR; i.e., the strength the GWC assigns to the
recommendation, which encompasses the anticipated
magnitude and judged certainty of beneﬁt in proportion
to risk) is assigned by the GWC. Concurrently, the Level of
Evidence (LOE) rates the scientiﬁc evidence supporting
the effect of the intervention on the basis of the type,
quality, quantity, and consistency of data from clinical
trials and other reports (Table 1) (4).
Relationships With Industry and Other Entities—The
ACC and AHA exclusively sponsor the work of GWCs,
without commercial support, and members volunteer
their time for this activity. The Task Force makes every
effort to avoid actual, potential, or perceived conﬂicts
of interest that might arise through relationships with
industry or other entities (RWI). All GWC members and
reviewers are required to fully disclose current industry
TABLE 1 Applying Classiﬁcation of Recommendations and Level of Evidence
A recommendation with Level of Evidence B or C does not imply that the recommendation is weak. Many important key clinical questions addressed in the guidelines
do not lend themselves to clinical trials. Although randomized trials are unavailable, there may be a very clear clinical consensus that a particular test or therapy is useful or
effective.
*Data available from clinical trials or registries about the usefulness/efﬁcacy in different subpopulations, such as sex, age, history of diabetes mellitus, history of prior myocardial
infarction, history of heart failure, and prior aspirin use.
†For comparative-effectiveness recommendations (Class I and IIa; Level of Evidence A and B only), studies that support the use of comparator verbs should involve direct com-
parisons of the treatments or strategies being evaluated.
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2376relationships or personal interests, from 12 months before
initiation of the writing effort. Management of RWI
involves selecting a balanced GWC and requires that both
the chair and a majority of GWC members have no rele-
vant RWI (see Appendix 1 for the deﬁnition of relevance).
GWC members are restricted with regard to writing or
voting on sections to which their RWI apply. In addition,
for transparency, GWC members’ comprehensive disclo-
sure information is available as an online supplement.
Comprehensive disclosure information for the Task Force
is available as an additional online supplement. The TaskForce strives to avoid bias by selecting experts from a broad
array of backgrounds representing different geographic re-
gions, genders, ethnicities, intellectual perspectives/biases,
and scopes of clinical practice. Selected organizations and
professional societies with related interests and expertise
are invited to participate as partners or collaborators.
Individualizing Care in Patients With Associated
Conditions and Comorbidities—The ACC and AHA recog-
nize the complexity of managing patients with multiple
conditions, compared with managing patients with a
single disease, and the challenge is compounded when
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2377CPGs for evaluation or treatment of several coexisting
illnesses are discordant or interacting (7). CPGs attempt to
deﬁne practices that meet the needs of patients in most,
but not all, circumstances and do not replace clinical
judgment.
Clinical Implementation—Management in accordance
with CPG recommendations is effective only when fol-
lowed; therefore, to enhance the patient’s commitment
to treatment and compliance with lifestyle adjustment,
clinicians should engage the patient to participate in
selecting interventions on the basis of the patient’s
individual values and preferences, taking associated
conditions and comorbidities into consideration (e.g.,
shared decision making). Consequently, there are cir-
cumstances in which deviations from these CPGs are
appropriate.
The recommendations in this CPG are the ofﬁcial policy
of the ACC and AHA until they are superseded by a pub-
lished addendum, focused update, or revised full-text
CPG. The reader is encouraged to consult the full-text
CPG (8) for additional guidance and details about peri-
operative cardiovascular evaluation and noncardiac sur-
gery, because the executive summary contains mainly the
recommendations.
Jeffrey L. Anderson, MD, FACC, FAHA
Chair, ACC/AHA Task Force on Practice Guidelines1. INTRODUCTION
1.1. Methodology and Evidence Review
The recommendations listed in this CPG are, whenever
possible, evidence based. In April 2013, an extensive
evidence review was conducted, which included a litera-
ture review through July 2013. Other selected references
published through May 2014 were also incorporated by
the GWC. Literature included was conducted in human
subjects, published in English, and indexed in MEDLINE
(through PubMed), EMBASE, the Cochrane Library,
Agency for Healthcare Research and Quality Reports,
and other selected databases relevant to this CPG.
The relevant data are included in evidence tables in
the Data Supplement available online. Key search
words included but were not limited to the following:
anesthesia protection; arrhythmia; atrial ﬁbrillation;
atrioventricular block; bundle branch block; cardiac
ischemia; cardioprotection; cardiovascular implantable
electronic device; conduction disturbance; dysrhythmia;
electrocardiography; electrocautery; electromagnetic inter-
ference; heart disease; heart failure; implantable
cardioverter-deﬁbrillator; intraoperative; left ventricular
ejection fraction; left ventricular function; myocardial
infarction; myocardial protection; National Surgical Qual-
ity Improvement Program; pacemaker; perioperative;perioperative pain management; perioperative risk; post-
operative; preoperative; preoperative evaluation; surgical
procedures; ventricular premature beats; ventricular
tachycardia; and volatile anesthetics.
An independent ERC was commissioned to perform a
systematic review of a critical question, the results of
which were incorporated into this CPG. See the systematic
review report published in conjunction with this CPG (9)
and its respective data supplements.
1.2. Organization of the GWC
The GWC was composed of clinicians with content and
methodological expertise, including general cardiologists,
subspecialty cardiologists, anesthesiologists, a surgeon, a
hospitalist, and a patient representative/lay volunteer.
The GWC included representatives from the ACC, AHA,
American College of Surgeons, American Society of
Anesthesiologists, American Society of Echocardiography,
American Society of Nuclear Cardiology, Heart Rhythm
Society, Society for Cardiovascular Angiography and
Interventions, Society of Cardiovascular Anesthesiolo-
gists, and Society for Vascular Medicine.
1.3. Document Review and Approval
This document was reviewed by 2 ofﬁcial reviewers each
from the ACC and the AHA; 1 reviewer each from the
American College of Surgeons, American Society of
Anesthesiologists, American Society of Echocardiography,
American Society of Nuclear Cardiology, Heart Rhythm
Society, Society for Cardiovascular Angiography and In-
terventions, Society of Cardiovascular Anesthesiologists,
Society of Hospital Medicine, and Society for Vascular
Medicine; and 24 individual content reviewers (including
members of the ACC Adult Congenital and Pediatric Car-
diology Section Leadership Council, ACC Electrophysi-
ology Section Leadership Council, ACC Heart Failure and
Transplant Section Leadership Council, ACC Interven-
tional Section Leadership Council, and ACC Surgeons’
Council). Reviewers’ RWI information was distributed to
the GWC and is published in this document (Appendix 2).
This document was approved for publication by the
governing bodies of the ACC and the AHA and endorsed
by the American College of Surgeons, American Society of
Anesthesiologists, American Society of Echocardiography,
American Society of Nuclear Cardiology, Heart Rhythm
Society, Society for Cardiovascular Angiography and
Interventions, Society of Cardiovascular Anesthesiolo-
gists, Society of Hospital Medicine, and Society of
Vascular Medicine.
1.4. Scope of the CPG
The focus of this CPG is the perioperative cardiovascular
evaluation and management of the adult patient
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2378undergoing noncardiac surgery. This includes preopera-
tive risk assessment and cardiovascular testing, as
well as (when indicated) perioperative pharmacological
(including anesthetic) management and perioperative
monitoring that includes devices and biochemical
markers. This CPG is intended to inform all the medical
professionals involved in the care of these patients.
The preoperative evaluation of the patient undergoing
noncardiac surgery can be performed for multiple pur-
poses, including 1) assessment of perioperative risk
(which can be used to inform the decision to proceed
or the choice of surgery and which includes the
patient’s perspective), 2) determination of the need for
changes in management, and 3) identiﬁcation of cardio-
vascular conditions or risk factors requiring longer-term
management. Changes in management can include the
decision to change medical therapies, the decision to
perform further cardiovascular interventions, or recom-
mendations about postoperative monitoring. This may
lead to recommendations and discussions with the
perioperative team about the optimal location and timing
of surgery (e.g., ambulatory surgery center versus outpa-
tient hospital, or inpatient admission) or alternative
strategies.
The key to optimal management is communication
among all of the relevant parties (i.e., surgeon, anesthe-
siologist, primary caregiver, and consultants) and the
patient. The goal of preoperative evaluation is to promote
patient engagement and facilitate shared decision
making by providing patients and their providers with
clear, understandable information about perioperative
cardiovascular risk in the context of the overall risk of
surgery.
The Task Force has chosen to make recommendations
about care management on the basis of available evidence
from studies of patients undergoing noncardiac surgery.
Extrapolation from data from the nonsurgical arena or
cardiac surgical arena was made only when no other data
were available and the beneﬁts of extrapolating the data
outweighed the risks.
During the initiation of the writing effort, concern was
expressed by Erasmus University about the scientiﬁc
integrity of studies led by Poldermans (10). The GWC
reviewed 2 reports from Erasmus University published on
the Internet (10,11), as well as other relevant articles on
this body of scientiﬁc investigation (12–14). The 2012
report from Erasmus University concluded that the
conduct in the DECREASE (Dutch Echocardiographic
Cardiac Risk Evaluation Applying Stress Echocardiogra-
phy) IV and V trials “was in several respects negligent
and scientiﬁcally incorrect” and that “essential source
documents are lacking” to make conclusions about
other studies led by Poldermans (10). Additionally,
Erasmus University was contacted to ensure that theGWC had up-to-date information. On the basis of the
published information, discussions between the Task
Force and GWC leadership ensued to determine how best
to treat any study in which Poldermans was the senior
investigator (i.e., either the ﬁrst or last author). The Task
Force developed the following framework for this
document:
1. The ERC will include the DECREASE trials in the
sensitivity analysis, but the systematic review report
will be based on the published data on perioperative
beta blockade, with data from all DECREASE trials
excluded.
2. The DECREASE trials and other derivative studies by
Poldermans should not be included in the CPG data
supplements and evidence tables.
3. If nonretracted DECREASE publications and/or other
derivative studies by Poldermans are relevant to the
topic, they can only be cited in the text with a comment
about the ﬁnding compared with the current recom-
mendation but should not form the basis of that
recommendation or be used as a reference for the
recommendation.
The Task Force and GWC believe that it is crucial for
the sake of transparency to include the nonretracted pub-
lications in the text of the document. This is particularly
important because further investigation is occurring
simultaneously with deliberation of the CPG recommenda-
tions. Because of the availability of new evidence and the
international impact of the controversy about the
DECREASE trials, the ACC/AHA and European Society of
Cardiology/European Society of Anesthesiology began
revising their respective CPGs concurrently. The respective
GWCs performed their literature reviews and analyses
independently and then developed their recommendations.
Once peer review of both CPGs was completed, the GWCs
chose to discuss their respective recommendations for
beta-blocker therapy and other relevant issues. Any differ-
ences in recommendations were discussed and clearly
articulated in the text; however, the GWCs aligned a few
recommendations to avoid confusion within the clinical
community, except where international practice variation
was prevalent.
In developing this CPG, the GWC reviewed prior pub-
lished CPGs and related statements. Table 2 lists these
publications and statements deemed pertinent to this
effort and is intended for use as a resource. However,
because of the availability of new evidence, the current
CPG may include recommendations that supersede those
previously published.
1.5. Deﬁnitions of Urgency and Risk
In describing the temporal necessity of operations in this
CPG, the GWC developed the following deﬁnitions by
TABLE 2 Associated CPGs and Statements
Title Organization
Publication Year
(Reference)
CPGs
Management of patients with atrial ﬁbrillation AHA/ACC/HRS 2014 (15)
Management of valvular heart disease AHA/ACC 2014 (16)
Management of heart failure ACC/AHA 2013 (17)
Performing a comprehensive transesophageal echocardiographic examination ASE/SCA 2013 (18)
Management of ST-elevation myocardial infarction ACC/AHA 2013 (19)
Diagnosis and management of patients with stable ischemic heart disease ACC/AHA/AATS/PCNA/SCAI/STS 2012 (19a)
2014 (20)
Focused update incorporated into the 2007 guidelines for the management of patients
with unstable angina/non–ST-elevation myocardial infarction*
ACC/AHA 2012 (21)
Red blood cell transfusion AABB 2012 (22)
Management of patients with peripheral artery disease: focused update and guideline ACC/AHA 2011 (23)
2006 (24)
Diagnosis and treatment of hypertrophic cardiomyopathy ACC/AHA 2011 (25)
Coronary artery bypass graft surgery ACC/AHA 2011 (26)
Percutaneous coronary intervention ACC/AHA/SCAI 2011 (27)
Perioperative transesophageal echocardiography American Society of Anesthesiologists/SCA 2010 (28)
Management of adults with congenital heart disease ACC/AHA 2008 (29)
Statements
Perioperative beta blockade in noncardiac surgery: a systematic review ACC/AHA 2014 (9)
Basic perioperative transesophageal echocardiography examination ASE/SCA 2013 (30)
Practice advisory for preanesthesia evaluation American Society of Anesthesiologists 2012 (31)
Cardiac disease evaluation and management among kidney and liver transplantation
candidates
AHA/ACC 2012 (32)
Inclusion of stroke in cardiovascular risk prediction instruments AHA/American Stroke Association 2012 (33)
Perioperative management of patients with implantable deﬁbrillators, pacemakers
and arrhythmia monitors: facilities and patient management
HRS/American Society of Anesthesiologists 2011 (34)
*The 2012 UA/NSTEMI CPG (21) is considered policy at the time of publication of this CPG; however, a full, revised CPG will be published in 2014.
AABB indicates American Association of Blood Banks; AATS, American Association for Thoracic Surgery; ACC, American College of Cardiology; AHA, American Heart Association; ASE,
American Society of Echocardiography; CPG, clinical practice guideline; HRS, Heart Rhythm Society; PCNA, Preventive Cardiovascular Nurses Association; SCAI, Society for Cardio-
vascular Angiography and Interventions; SCA, Society of Cardiovascular Anesthesiologists; STEMI, ST-elevation myocardial infarction; STS, Society of Thoracic Surgeons; and UA/
NSTEMI, unstable angina/non–ST-elevation myocardial infarction.
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2379consensus. An emergency procedure is one in which life or
limb is threatened if not in the operating room, where
there is time for no or very limited or minimal clinical
evaluation, typically within <6 hours. An urgent proce-
dure is one in which there may be time for a limited
clinical evaluation, usually when life or limb is threatened
if not in the operating room, typically between 6 and
24 hours. A time-sensitive procedure is one in which a
delay of >1 to 6 weeks to allow for an evaluation and
signiﬁcant changes in management will negatively affect
outcome. Most oncologic procedures would fall into this
category. An elective procedure is one in which the
procedure could be delayed for up to 1 year. Individual
institutions may use slightly different deﬁnitions, but
this framework could be mapped to local categories. A
low-risk procedure is one in which the combined surgicaland patient characteristics predict a risk of a major
adverse cardiac event (MACE) of death or myocardial
infarction (MI) of <1%. Selected examples of low-risk
procedures include cataract and plastic surgery (35,36).
Procedures with a risk of MACE of $1% are considered
elevated risk. Many previous risk-stratiﬁcation schema
have included intermediate- and high-risk classiﬁcations.
Because recommendations for intermediate- and high-
risk procedures are similar, classiﬁcation into 2 cate-
gories simpliﬁes the recommendations without loss of
ﬁdelity. Additionally, a risk calculator has been developed
that allows more precise calculation of surgical risk,
which can be incorporated into perioperative decision
making (37). Approaches to establishing low and elevated
risk are developed more fully in Section 3 in the full-
text CPG.
*Features of increased perioperative risk in patients with pulmonary hyper-
tension include: 1) diagnosis of Group 1 pulmonary hypertension (i.e., pulmo-
nary arterial hypertension), 2) other forms of pulmonary hypertension
associated with high pulmonary pressures (pulmonary artery systolic pressures
>70 mmHg) and/or moderate or greater right ventricular dilatation and/or
dysfunction and/or pulmonary vascular resistance >3 Wood units, and 3)
World Health Organization/New York Heart Association class III or IV symp-
toms attributable to pulmonary hypertension (52–58).
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23802. CLINICAL RISK FACTORS: RECOMMENDATIONS
2.1. Valvular Heart Disease
See the 2014 valvular heart disease CPG for the complete
set of recommendations and speciﬁc deﬁnitions of dis-
ease severity (16).
CLASS I
1. It is recommended that patients with clinically suspected
moderate or greater degrees of valvular stenosis or
regurgitation undergo preoperative echocardiography if
there has been either 1) no prior echocardiography within
1 year or 2) a signiﬁcant change in clinical status or
physical examination since last evaluation (39). (Level of
Evidence: C)
2. For adults who meet standard indications for valvular
intervention (replacement and repair) on the basis of
symptoms and severity of stenosis or regurgitation,
valvular intervention before elective noncardiac surgery is
effective in reducing perioperative risk (16). (Level of
Evidence: C)
CLASS IIa
1. Elevated-risk elective noncardiac surgery with appropriate
intraoperative and postoperative hemodynamic monitoring
is reasonable to perform in patients with asymptomatic
severe aortic stenosis (40–50). (Level of Evidence: B)
2. Elevated-risk elective noncardiac surgery with appropriate
intraoperative and postoperative hemodynamic monitoring
is reasonable in adults with asymptomatic severe MR. (Level
of Evidence: C)
3. Elevated-risk elective noncardiac surgery with appropriate
intraoperative and postoperative hemodynamic monitoring
is reasonable in adults with asymptomatic severe aortic
regurgitation and a normal left ventricular ejection fraction.
(Level of Evidence: C)
CLASS IIb
1. Elevated-risk elective noncardiac surgery using appropriate
intraoperative and postoperative hemodynamic monitoring
may be reasonable in asymptomatic patients with severe
mitral stenosis if valve morphology is not favorable for
percutaneous mitral balloon commissurotomy. (Level of
Evidence: C)
2.2. Other Clinical Risk Factors
See Section 5.8 for intraoperative/postoperative cardiovas-
cular implantable electronic device (CIED) management.
CLASS I
1. Before elective surgery in a patient with a CIED, the surgical/
procedure team and clinician following the CIED should
communicate in advance to plan perioperative management
of the CIED. (Level of Evidence: C)2. Chronic pulmonary vascular targeted therapy (i.e., phos-
phodiesterase type 5 inhibitors, soluble guanylate cyclase
stimulators, endothelin receptor antagonists, and prosta-
noids) should be continued unless contraindicated or not
tolerated in patients with pulmonary hypertension who are
undergoing noncardiac surgery. (Level of Evidence: C)
CLASS IIa
1. Unless the risks of delay outweigh the potential beneﬁts, pre-
operative evaluation by a pulmonary hypertension specialist
before noncardiac surgery can be beneﬁcial for patients with
pulmonary hypertension, particularly for those with features
of increased perioperative risk (51)*. (Level of Evidence: C)
3. APPROACH TO PERIOPERATIVE
CARDIAC TESTING: RECOMMENDATIONS
3.1. Multivariate Risk Indices
CLASS IIa
1. A validated risk-prediction tool can be useful in predicting
the risk of perioperative MACE in patients undergoing
noncardiac surgery (59–61). (Level of Evidence: B)
CLASS III: NO BENEFIT
1. For patients with a low risk of perioperative MACE, further
testing is not recommended before the planned operation
(35,36). (Level of Evidence: B)
3.2. Stepwise Approach to Perioperative Cardiac Assessment:
Treatment Algorithm
See Figure 1 for a stepwise approach to perioperative
cardiac assessment for CAD.
The GWC developed an algorithmic approach to
perioperative cardiac assessment on the basis of the
available evidence and expert opinion, the rationale of
which is outlined throughout the CPG. The algorithm
incorporates the perspectives of clinicians caring for the
patient to provide informed consent and help guide peri-
operativemanagement to minimize risk. It is also crucial to
incorporate the patient’s perspective with regard to the
assessment of the risk of surgery or alternative therapy and
the risk of any GDMT or coronary and valvular in-
terventions before noncardiac surgery. Patients may elect
to forgo a surgical intervention if the risk of perioperative
morbidity and mortality is extremely high; soliciting this
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2381information from the patient before surgery is a key part of
shared decision making.
4. SUPPLEMENTAL PREOPERATIVE EVALUATION:
RECOMMENDATIONS
See Table 3 for a summary of recommendations for sup-
plemental preoperative evaluation.FIGURE 1 Stepwise Approach to Perioperative Cardiac Assessment for CAD4.1. The 12-Lead Electrocardiogram
CLASS IIa
1. Preoperative resting 12-lead electrocardiogram (ECG) is
reasonable for patients with known coronary heart
disease, signiﬁcant arrhythmia, peripheral arterial disease,
cerebrovascular disease, or other signiﬁcant structural heart
disease, except for those undergoing low-risk surgery
(64–66). (Level of Evidence: B)Continued on the next page
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2382CLASS IIb
1. Preoperative resting 12-lead ECG may be considered for
asymptomatic patients without known coronary heart
disease, except for those undergoing low-risk surgery
(59,65–67). (Level of Evidence: B)
CLASS III: NO BENEFIT
1. Routine preoperative resting 12-lead ECG is not useful
for asymptomatic patients undergoing low-risk surgical
procedures (36,68). (Level of Evidence: B)4.2. Assessment of Left Ventricular Function
CLASS IIa
1. It is reasonable for patients with dyspnea of unknown origin
to undergo preoperative evaluation of left ventricular (LV)
function. (Level of Evidence: C)
2. It is reasonable for patients with heart failure (HF) with wors-
ening dyspnea or other change in clinical status to undergo
preoperative evaluation of LV function. (Level of Evidence: C)
CLASS IIb
1. Reassessment of LV function in clinically stable patients with
previously documented LV dysfunction may be considered
if there has been no assessment within a year. (Level of
Evidence: C)
CLASS III: NO BENEFIT
1. Routine preoperative evaluation of LV function is not rec-
ommended (69–71). (Level of Evidence: B)Colors correspond to the Classes of Recommendations in Table 1. Step 1: In patie
urgency of surgery. If an emergency, then determine the clinical risk factors tha
appropriate monitoring and management strategies based on the clinical assessm
patients with symptomatic HF, VHD, or arrhythmias, see Sections 2.2, 2.4, and 2.5
If the surgery is urgent or elective, determine if the patient has an ACS. If yes, t
GDMT according to the UA/NSTEMI and STEMI CPGs (19,21). Step 3: If the patie
MACE on the basis of the combined clinical/surgical risk. This estimate can use t
riskcalculator.facs.org) or incorporate the RCRI (62) with an estimation of surgic
ophthalmologic surgery), even with multiple risk factors, would have a low risk o
factors would have an elevated risk of MACE (see Section 3 in the full-text CPG).
is needed, and the patient may proceed to surgery (Section 3 in the full-text CPG)
capacity with an objective measure or scale such as the DASI (63). If the patient
proceed to surgery without further evaluation (Section 4.1 in the full-text CPG). St
the clinician should consult with the patient and perioperative team to determine
perform original surgery or willingness to undergo CABG or PCI, depending on the
testing is appropriate. In those patients with unknown functional capacity, exercis
consider coronary angiography and revascularization depending on the extent of
consider alternative strategies, such as noninvasive treatment of the indication for
proceed to surgery according to GDMT (Section 4.3). Step 7: If testing will not im
consider alternative strategies, such as noninvasive treatment of the indication for
coronary syndrome; CABG, coronary artery bypass graft; CAD, coronary artery d
GDMT, guideline-directed medical therapy; HF, heart failure; MACE, major advers
Surgical Quality Improvement Program; PCI, percutaneous coronary intervention;
UA/NSTEMI, unstable angina/non–ST-elevation myocardial infarction; and VHD,
FIGURE 14.3. Exercise Testing
CLASS IIa
1. For patients with elevated risk and excellent (>10 metabolic
equivalents [METs]) functional capacity, it is reasonable to
forgo further exercise testing with cardiac imaging and
proceed to surgery (72–76). (Level of Evidence: B)
CLASS IIb
1. For patients with elevated risk and unknown functional
capacity, it may be reasonable to perform exercise testing to
assess for functional capacity if it will change management
(75–77). (Level of Evidence: B)
2. Cardiopulmonary exercise testing may be considered for pa-
tients undergoing elevated risk procedures in whom func-
tional capacity is unknown (78–86). (Level of Evidence: B)
3. For patients with elevated risk and moderate to good
($4 METs to 10 METs) functional capacity, it may be
reasonable to forgo further exercise testing with cardiac im-
aging and proceed to surgery (72–74). (Level of Evidence: B)
4. For patients with elevated risk and poor (<4 METs) or
unknown functional capacity, it may be reasonable to
perform exercise testing with cardiac imaging to assess for
myocardial ischemia if it will change management. (Level of
Evidence: C)
CLASS III: NO BENEFIT
1. Routine screening with noninvasive stress testing is not
useful for patients at low risk for noncardiac surgery (87,88).
(Level of Evidence: B)nts scheduled for surgery with risk factors for or known CAD, determine the
t may inﬂuence perioperative management and proceed to surgery with
ent (see Section 2.5 in the full-text CPG for more information on CAD). (For
in the full-text CPG for information on evaluation and management.) Step 2:
hen refer patient for cardiology evaluation and management according to
nt has risk factors for stable CAD, then estimate the perioperative risk of
he American College of Surgeons NSQIP risk calculator (http://www.
al risk. For example, a patient undergoing very low-risk surgery (e.g.,
f MACE, whereas a patient undergoing major vascular surgery with few risk
Step 4: If the patient has a low risk of MACE (<1%), then no further testing
. Step 5: If the patient is at elevated risk of MACE, then determine functional
has moderate, good, or excellent functional capacity ($4 METs), then
ep 6: If the patient has poor (<4METs) or unknown functional capacity, then
whether further testing will impact patient decision making (e.g., decision to
results of the test) or perioperative care. If yes, then pharmacological stress
e stress testing may be reasonable to perform. If the stress test is abnormal,
the abnormal test. The patient can then proceed to surgery with GDMT or
surgery (e.g., radiation therapy for cancer) or palliation. If the test is normal,
pact decision making or care, then proceed to surgery according to GDMT or
surgery (e.g., radiation therapy for cancer) or palliation. ACS indicates acute
isease; CPG, clinical practice guideline; DASI, Duke Activity Status Index;
e cardiac event; MET, metabolic equivalent; NB, No Beneﬁt; NSQIP, National
RCRI, Revised Cardiac Risk Index; STEMI, ST-elevation myocardial infarction;
valvular heart disease.
TABLE 3 Summary of Recommendations for Supplemental Preoperative Evaluation
Recommendations COR LOE References
The 12-lead ECG
Preoperative resting 12-lead ECG is reasonable for patients with known coronary heart disease or other
signiﬁcant structural heart disease, except for low-risk surgery
IIa B (64–66)
Preoperative resting 12-lead ECG may be considered for asymptomatic patients, except for low-risk surgery IIb B (59,65–67)
Routine preoperative resting 12-lead ECG is not useful for asymptomatic patients undergoing low-risk
surgical procedures
III: No Beneﬁt B (36,68)
Assessment of LV function
It is reasonable for patients with dyspnea of unknown origin to undergo preoperative evaluation
of LV function
IIa C N/A
It is reasonable for patients with HF with worsening dyspnea or other change in clinical status to undergo
preoperative evaluation of LV function
IIa C N/A
Reassessment of LV function in clinically stable patients may be considered IIb C N/A
Routine preoperative evaluation of LV function is not recommended III: No Beneﬁt B (69–71)
Exercise stress testing
For patients with elevated risk and excellent functional capacity, it is reasonable to forgo further exercise
testing and proceed to surgery
IIa B (72–76)
For patients with elevated risk and unknown functional capacity it may be reasonable to perform exercise
testing to assess for functional capacity if it will change management
IIb B (75–77)
Cardiopulmonary exercise testing may be considered for patients undergoing elevated risk procedures IIb B (78–86)
For patients with elevated risk and moderate to good functional capacity, it may be reasonable to forgo
further exercise testing and proceed to surgery
IIb B (72–74)
For patients with elevated risk and poor or unknown functional capacity it may be reasonable to perform
exercise testing with cardiac imaging to assess for myocardial ischemia
IIb C N/A
Routine screening with noninvasive stress testing is not useful for low-risk noncardiac surgery III: No Beneﬁt B (87,88)
Noninvasive pharmacological stress testing before noncardiac surgery
It is reasonable for patients at elevated risk for noncardiac surgery with poor functional capacity
to undergo either DSE or MPI if it will change management
IIa B (89–93)
Routine screening with noninvasive stress testing is not useful for low-risk noncardiac surgery III: No Beneﬁt B (87,88)
Preoperative coronary angiography
Routine preoperative coronary angiography is not recommended III: No Beneﬁt C N/A
COR indicates Class of Recommendation; DSE, dobutamine stress echocardiogram; ECG, electrocardiogram; HF, heart failure; LOE, Level of Evidence; LV, left ventricular; MPI,
myocardial perfusion imaging; and N/A, not applicable.
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23834.4. Noninvasive Pharmacological Stress Testing Before
Noncardiac Surgery
CLASS IIa
1. It is reasonable for patients who are at an elevated risk
for noncardiac surgery and have poor functional capacity
(<4 METs) to undergo noninvasive pharmacological stress
testing (either dobutamine stress echocardiogram or phar-
macological stress myocardial perfusion imaging) if it will
change management (89–93). (Level of Evidence: B)
CLASS III: NO BENEFIT
1. Routine screening with noninvasive stress testing is not
useful for patients undergoing low-risk noncardiac surgery
(87,88). (Level of Evidence: B)
4.5. Preoperative Coronary Angiography
CLASS III: NO BENEFIT
1. Routine preoperative coronary angiography is not recom-
mended. (Level of Evidence: C)5. PERIOPERATIVE THERAPY:
RECOMMENDATIONS
See Table 4 for a summary of recommendations for peri-
operative therapy.
5.1. Coronary Revascularization Before Noncardiac Surgery
CLASS I
1. Revascularization before noncardiac surgery is recom-
mended in circumstances in which revascularization is
indicated according to existing CPGs (26,27). (Level of
Evidence: C) (See Table A in Appendix 3 for related recom-
mendations.)CLASS III: NO BENEFIT
1. It is not recommended that routine coronary revasculariza-
tion be performed before noncardiac surgery exclusively
to reduce perioperative cardiac events (97). (Level of
Evidence: B)
TABLE 4 Summary of Recommendations for Perioperative Therapy
Recommendations COR LOE References
Coronary revascularization before noncardiac surgery
Revascularization before noncardiac surgery is recommended when indicated by
existing CPGs
I C (26,27)
Coronary revascularization is not recommended before noncardiac surgery exclusively
to reduce perioperative cardiac events
III: No Beneﬁt B (97)
Timing of elective noncardiac surgery in patients with previous PCI
Noncardiac surgery should be delayed after PCI I C: 14 d after balloon
angioplasty
N/A
B: 30 d after BMS
implantation
(99–101)
Noncardiac surgery should optimally be delayed 365 d after DES implantation I B (102–105)
A consensus decision as to the relative risks of discontinuation or continuation of
antiplatelet therapy can be useful
IIa C N/A
Elective noncardiac surgery after DES implantation may be considered after 180 d IIb* B (102,106)
Elective noncardiac surgery should not be performed in patients in whom DAPT will
need to be discontinued perioperatively within 30 d after BMS implantation or
within 12 mo after DES implantation
III: Harm B (99–105,107)
Elective noncardiac surgery should not be performed within 14 d of balloon angioplasty
in patients in whom aspirin will need to be discontinued perioperatively
III: Harm C N/A
Perioperative beta-blocker therapy
Continue beta blockers in patients who are on beta blockers chronically I B SR† (111–117)
Guide management of beta blockers after surgery by clinical circumstances IIa B SR† (110,117,118)
In patients with intermediate- or high-risk preoperative tests, it may be reasonable
to begin beta blockers
IIb C SR† (119)
In patients with $3 RCRI factors, it may be reasonable to begin beta blockers
before surgery
IIb B SR† (117)
Initiating beta blockers in the perioperative setting as an approach to reducing
perioperative risk is of uncertain beneﬁt in those with a long-term indication
but no other RCRI risk factors
IIb B SR† (111,117,120)
It may be reasonable to begin perioperative beta blockers long enough in advance to
assess safety and tolerability, preferably >1 d before surgery
IIb B SR† (110,121–123)
Beta-blocker therapy should not be started on the d of surgery III: Harm B SR† (110)
Perioperative statin therapy
Continue statins in patients currently taking statins I B (131–134)
Perioperative initiation of statin use is reasonable in patients undergoing vascular surgery IIa B (135)
Perioperative initiation of statins may be considered in patients with a clinical risk factor
who are undergoing elevated-risk procedures
IIb C N/A
Alpha-2 agonists
Alpha-2 agonists are not recommended for prevention of cardiac events III: No Beneﬁt B (136–140)
ACE inhibitors
Continuation of ACE inhibitors or ARBs is reasonable perioperatively IIa B (141,142)
If ACE inhibitors or ARBs are held before surgery, it is reasonable to restart as soon as
clinically feasible postoperatively
IIa C N/A
Antiplatelet agents
Continue DAPT in patients undergoing urgent noncardiac surgery during the ﬁrst 4 to 6 wk
after BMS or DES implantation, unless the risk of bleeding outweighs the beneﬁt of
stent thrombosis prevention
I C N/A
In patients with stents undergoing surgery that requires discontinuation of P2Y12 inhibitors,
continue aspirin and restart the P2Y12 platelet receptor–inhibitor as soon as possible
after surgery
I C N/A
Management of perioperative antiplatelet therapy should be determined by consensus of
treating clinicians and the patient
I C N/A
In patients undergoing nonemergency/nonurgent noncardiac surgery without prior coronary
stenting, it may be reasonable to continue aspirin when the risk of increased cardiac
events outweighs the risk of increased bleeding
IIb B (143,144)
Continued on the next page
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TABLE 4 Continued
Recommendations COR LOE References
Initiation or continuation of aspirin is not beneﬁcial in patients undergoing elective
noncardiac noncarotid surgery who have not had previous coronary stenting
III: No Beneﬁt B (143)
C: If risk of ischemic
events outweighs
risk of surgical
bleeding
N/A
Perioperative management of patients with CIEDs
Patients with ICDs should be on a cardiac monitor continuously during the entire period of
inactivation, and external deﬁbrillation equipment should be available. Ensure that
ICDs are reprogrammed to active therapy
I C (145)
*Because of new evidence, this is a new recommendation since the publication of the 2011 PCI CPG (27).
†These recommendations have been designated with a SR to emphasize the rigor of support from the ERC’s systematic review.
ACE indicates angiotensin-converting-enzyme; ARB, angiotensin-receptor blocker; BMS, bare-metal stent; CIED, cardiovascular implantable electronic device; COR, Class of
Recommendation; CPG, clinical practice guideline; DAPT, dual antiplatelet therapy; DES, drug-eluting stent; ERC, Evidence Review Committee; ICD, implantable cardioverter-
deﬁbrillator; LOE, Level of Evidence; N/A, not applicable; PCI, percutaneous coronary intervention; RCRI, Revised Cardiac Risk Index; and SR, systematic review.
*Because of new evidence, this is a new recommendation since the publication
of the 2011 PCI CPG (27).
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noncardiac procedures and whose evaluation recommends
coronary artery bypass graft surgery should undergo coro-
nary revascularization before an elevated-risk surgical pro-
cedure (98). The cumulative mortality and morbidity risks of
both the coronary revascularization procedure and the
noncardiac surgery should be weighed carefully in light of
the individual patient’s overall health, functional status, and
prognosis. The indications for preoperative surgical coronary
revascularization are identical to those recommended in
the 2011 coronary artery bypass graft surgery CPG and the
2011 percutaneous coronary intervention (PCI) CPG and
the accumulated data on which those conclusions were
based (26,27) (See Table A in Appendix 3 for the related
recommendations).
The role of preoperative PCI in reducing untoward
perioperative cardiac complications is uncertain given
the available data. Performing PCI before noncardiac
surgery should be limited to 1) patients with left main
disease whose comorbidities preclude bypass surgery
without undue risk and 2) patients with unstable coronary
artery disease who would be appropriate candidates
for emergency or urgent revascularization (26,27).
Patients with ST-elevation MI or non–ST-elevation
acute coronary syndrome beneﬁt from early invasive
management (96). In such patients, in whom noncardiac
surgery is time sensitive despite an increased risk in
the perioperative period, a strategy of balloon angioplasty
or bare-metal stent (BMS) implantation should be
considered.
5.2. Timing of Elective Noncardiac Surgery in
Patients With Previous PCI
CLASS I
1. Elective noncardiac surgery should be delayed 14 days
after balloon angioplasty (Level of Evidence: C) and
30 days after BMS implantation (99–101). (Level of
Evidence B)2. Elective noncardiac surgery should optimally be delayed 365
days after drug-eluting stent (DES) implantation (102–105).
(Level of Evidence: B)
CLASS IIa
1. In patients in whom noncardiac surgery is required, a
consensus decision among treating clinicians as to the
relative risks of surgery and discontinuation or continua-
tion of antiplatelet therapy can be useful. (Level of
Evidence: C)
CLASS IIb*
1. Elective noncardiac surgery after DES implantation may be
considered after 180 days if the risk of further delay is
greater than the expected risks of ischemia and stent
thrombosis (102,106). (Level of Evidence: B)
CLASS III: HARM
1. Elective noncardiac surgery should not be performed within
30 days after BMS implantation or within 12 months after
DES implantation in patients in whom dual antiplatelet
therapy will need to be discontinued perioperatively
(99–105,107). (Level of Evidence: B)
2. Elective noncardiac surgery should not be performed within
14 days of balloon angioplasty in patients in whom aspirin
will need to be discontinued perioperatively. (Level of
Evidence: C)5.3. Perioperative Beta-Blocker Therapy
See the ERC systematic review report, “Perioperative Beta
Blockade in Noncardiac Surgery: A Systematic Review for
the 2014 ACC/AHA Guideline on Perioperative Cardio-
vascular Evaluation and Management of Patients Under-
going Noncardiac Surgery” for the complete evidence
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recommendations have been designated with a SR to
emphasize the rigor of support from the ERC’s systematic
review.
As noted in the Scope of this CPG (Section 1.4), the
recommendations in Section 5.3 are based on a separately
commissioned review of the available evidence, the
results of which were used to frame our decision
making. Full details are provided in the ERC’s systematic
review report (9) and data supplements. However,
3 key ﬁndings were powerful inﬂuences on this CPG’s
recommendations:
1. The systematic review suggests that preoperative use
of beta blockers was associated with a reduction
in cardiac events in the studies examined, but few
data support the effectiveness of preoperative admin-
istration of beta blockers to reduce risk of surgical
death.
2. Consistent and clear associations exist between beta-
blocker administration and adverse outcomes, such as
bradycardia and stroke.
3. These ﬁndings were quite consistent even when the
DECREASE studies (108,109) in question or the POISE
(Perioperative Ischemic Evaluation) study (110) were
excluded. Stated alternatively, exclusion of these
studies did not substantially affect estimates of risk or
beneﬁt.CLASS I
1. Beta blockers should be continued in patients undergoing
surgery who have been on beta blockers chronically
(111–117). (Level of Evidence: B) SRCLASS IIa
1. It is reasonable for the management of beta blockers after
surgery to be guided by clinical circumstances, independent
of when the agent was started (110,117,118). (Level of
Evidence: B) SRCLASS IIb
1. In patients with intermediate- or high-risk myocardial
ischemia noted in preoperative risk stratiﬁcation tests, it
may be reasonable to begin perioperative beta blockers
(119). (Level of Evidence: C) SR
2. In patients with 3 or more RCRI risk factors (e.g., dia-
betes mellitus, HF, coronary artery disease, renal insuf-
ﬁciency, cerebrovascular accident), it may be reasonable
to begin beta blockers before surgery (117). (Level of
Evidence: B) SR
3. In patients with a compelling long-term indication for beta-
blocker therapy but no other RCRI risk factors, initiating
beta blockers in the perioperative setting as an approach
to reduce perioperative risk is of uncertain beneﬁt
(111,117,120). (Level of Evidence: B) SR4. In patients in whom beta-blocker therapy is initiated, it may
be reasonable to begin perioperative beta blockers long
enough in advance to assess safety and tolerability, prefer-
ably more than 1 day before surgery (110,121–123). (Level of
Evidence: B) SRCLASS III: HARM
1. Beta-blocker therapy should not be started on the day of
surgery (110). (Level of Evidence: B) SR
If well tolerated, continuing beta blockers in patients who are
currently receiving them for longitudinal reasons, particu-
larly when longitudinal treatment is provided according to
GDMT, such as for MI, is recommended (see Table B in
Appendix 3 for applicable recommendations from the 2011
secondary prevention CPG) (124). This recommendation is
consistent with the Surgical Care Improvement Project
National Measures (CARD-2) as of November 2013 (125).
Particular attention should be paid to the need to modify or
temporarily discontinue beta blockers as clinical circum-
stances (e.g., hypotension, bradycardia (126), bleeding) (118)
dictate.
The risks and beneﬁts of perioperative beta blocker use
appear to be favorable in patients who have intermediate-
or high-risk myocardial ischemia noted on preoperative
stress testing (119,127). The decision to begin beta
blockers should be inﬂuenced by whether a patient is at
risk for stroke (128–130) and whether the patient has other
relative contraindications (such as uncompensated HF).
Observational data suggest that patients appear to beneﬁt
from use of beta blockers in the perioperative setting if
they have $3 RCRI risk factors. It may be reasonable to
begin beta blockers long enough in advance of the oper-
ative date that clinical effectiveness and tolerability can
be assessed (110,121–123). Starting the medication 2 to 7
days before surgery may be preferred, but few data sup-
port the need to start beta blockers >30 days beforehand
(121–123).5.4. Perioperative Statin Therapy
CLASS I
1. Statins should be continued in patients currently taking
statins and scheduled for noncardiac surgery (131–134).
(Level of Evidence: B)
CLASS IIa
1. Perioperative initiation of statin use is reasonable in
patients undergoing vascular surgery (135). (Level of
Evidence: B)
CLASS IIb
1. Perioperative initiation of statins may be considered in
patients with clinical indications according to GDMT who are
undergoing elevated-risk procedures. (Level of Evidence: C)
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23875.5. Alpha-2 Agonists
CLASS III: NO BENEFIT
1. Alpha-2 agonists for prevention of cardiac events are not
recommended in patients who are undergoing noncardiac
surgery (136–140). (Level of Evidence: B)5.6. Angiotensin-Converting Enzyme Inhibitors
CLASS IIa
1. Continuation of angiotensin-converting enzyme inhibitors or
angiotensin-receptor blockers perioperatively is reasonable
(141,142). (Level of Evidence: B)
2. If angiotensin-converting enzyme inhibitors or angiotensin-
receptor blockers are held before surgery, it is reasonable
to restart as soon as clinically feasible postoperatively.
(Level of Evidence: C)5.7. Antiplatelet Agents
Please see Figure 2 for an algorithm for antiplatelet man-
agement in patients with PCI and noncardiac surgery.
CLASS I
1. In patients undergoing urgent noncardiac surgery during the
ﬁrst 4 to 6 weeks after BMS or DES implantation, dual
antiplatelet therapy should be continued unless the relative
risk of bleeding outweighs the beneﬁt of the prevention of
stent thrombosis. (Level of Evidence: C)
2. In patients who have received coronary stents and must
undergo surgical procedures that mandate the discontinua-
tion of P2Y12 platelet receptor–inhibitor therapy, it is
recommended that aspirin be continued if possible and the
P2Y12 platelet receptor–inhibitor be restarted as soon as
possible after surgery. (Level of Evidence: C)
3. Management of the perioperative antiplatelet therapy
should be determined by a consensus of the surgeon, anes-
thesiologist, cardiologist, and patient, who should weigh
the relative risk of bleeding with that of stent thrombosis.
(Level of Evidence: C)
CLASS IIb
1. In patients undergoing nonemergency/nonurgent noncar-
diac surgery who have not had previous coronary stent-
ing, it may be reasonable to continue aspirin when
the risk of potential increased cardiac events outweighs
the risk of increased bleeding (143,144). (Level of
Evidence: B)
CLASS III: NO BENEFIT
1. Initiation or continuation of aspirin is not beneﬁcial in
patients undergoing elective noncardiac noncarotid surgery
who have not had previous coronary stenting (143)
(Level of Evidence: B), unless the risk of ischemic events
outweighs the risk of surgical bleeding. (Level of
Evidence: C)5.8. Perioperative Management of Patients With CIEDs
CLASS I
1. Patients with implantable cardioverter-deﬁbrillators who
have preoperative reprogramming to inactivate tachytherapy
should be on cardiac monitoring continuously during the
entire period of inactivation, and external deﬁbrillation
equipment should be readily available. Systems should be in
place to ensure that implantable cardioverter-deﬁbrillators
are reprogrammed to active therapy before discontinuation
of cardiac monitoring and discharge from the facility (145).
(Level of Evidence: C)6. ANESTHETIC CONSIDERATION AND
INTRAOPERATIVE MANAGEMENT:
RECOMMENDATIONS
See Table 5 for a summary of recommendations for anes-
thetic consideration and intraoperative management.
6.1. Choice of Anesthetic Technique and Agent
CLASS IIa
1. Use of either a volatile anesthetic agent or total intravenous
anesthesia is reasonable for patients undergoing noncardiac
surgery, and the choice is determined by factors other than
the prevention of myocardial ischemia and MI (146,147).
(Level of Evidence: A)
2. Neuraxial anesthesia for postoperative pain relief can be
effective in patients undergoing abdominal aortic surgery to
decrease the incidence of perioperative MI (148). (Level of
Evidence: B)
CLASS IIb
1. Perioperative epidural analgesia may be considered to
decrease the incidence of preoperative cardiac events in
patients with a hip fracture (149). (Level of Evidence: B)6.2. Intraoperative Management
CLASS IIa
1. The emergency use of perioperative transesophageal echo-
cardiogram is reasonable in patients with hemodynamic
instability undergoing noncardiac surgery to determine the
cause of hemodynamic instability when it persists despite
attempted corrective therapy, if expertise is readily avail-
able. (Level of Evidence: C)
CLASS IIb
1. Maintenance of normothermia may be reasonable to reduce
perioperative cardiac events in patients undergoing non-
cardiac surgery (150,151). (Level of Evidence: B)
2. Use of hemodynamic assist devices may be considered when
urgent or emergency noncardiac surgery is required in the
setting of acute severe cardiac dysfunction (i.e., acute MI,
FIGURE 2 Algorithm for Antiplatelet Management in Patients With PCI and Noncardiac Surgery
Colors correspond to the Classes of Recommendations in Table 1. *Assuming patient is currently on DAPT. ASA indicates aspirin; ASAP, as soon as possible;
BMS, bare-metal stent; DAPT, dual antiplatelet therapy; DES, drug-eluting stent; and PCI, percutaneous coronary intervention.
Fleisher et al. J A C C V O L . 6 4 , N O . 2 2 , 2 0 1 4
ACC/AHA Perioperative Clinical Practice Guideline: Executive Summary D E C E M B E R 9 , 2 0 1 4 : 2 3 7 3 – 4 0 5
2388cardiogenic shock) that cannot be corrected before surgery.
(Level of Evidence: C)
3. The use of pulmonary artery catheterization may be
considered when underlying medical conditions that signif-
icantly affect hemodynamics (i.e., HF, severe valvular dis-
ease, combined shock states) cannot be corrected before
surgery. (Level of Evidence: C)CLASS III: NO BENEFIT
1. Routine use of pulmonary artery catheterization in patients,
even those with elevated risk, is not recommended
(152–154). (Level of Evidence: A)
2. Prophylactic intravenous nitroglycerin is not effective in
reducing myocardial ischemia in patients undergoing
noncardiac surgery (137,155,156). (Level of Evidence: B)
TABLE 5 Summary of Recommendations for Anesthetic Consideration and Intraoperative Management
Recommendations COR LOE References
Choice of anesthetic technique and agent
Use of either a volatile anesthetic agent or total intravenous anesthesia is reasonable for patients
undergoing noncardiac surgery
IIa A (146,147)
Neuraxial anesthesia for postoperative pain relief can be effective to reduce MI in patients
undergoing abdominal aortic surgery
IIa B (148)
Preoperative epidural analgesia may be considered to decrease the incidence of preoperative cardiac
events in patients with hip fracture
IIb B (149)
Nitroglycerin management
Emergency use of perioperative TEE in patients with hemodynamic instability is reasonable in patients
undergoing noncardiac surgery if expertise is readily available
IIa C N/A
Maintenance of normothermia may be reasonable to reduce perioperative cardiac events IIb B (150,151)
Use of hemodynamic assist devices may be considered when urgent or emergency noncardiac surgery
is required in the setting of acute severe cardiac dysfunction
IIb C N/A
Use of pulmonary artery catheterization may be considered when underlying medical conditions
that signiﬁcantly affect hemodynamics cannot be corrected before surgery
IIb C N/A
Routine use of pulmonary artery catheterization is not recommended III: No Beneﬁt A (152–154)
Prophylactic intravenous nitroglycerin is not effective in reducing myocardial ischemia in patients
undergoing noncardiac surgery
III: No Beneﬁt B (137,155,156)
Routine use of intraoperative TEE during noncardiac surgery is not recommended III: No Beneﬁt C N/A
COR indicates Class of Recommendation; LOE, Level of Evidence; MI, myocardial infarction; N/A, not applicable; and TEE, transesophageal echocardiogram.
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23893. The routine use of intraoperative transesophageal echocar-
diogram during noncardiac surgery to screen for cardiac
abnormalities or to monitor for myocardial ischemia is not
recommended in patients without risk factors or procedural
risks for signiﬁcant hemodynamic, pulmonary, or neurologic
compromise. (Level of Evidence: C)
7. SURVEILLANCE AND MANAGEMENT FOR
PERIOPERATIVE MI: RECOMMENDATIONS
CLASS I
1. Measurement of troponin levels is recommended in the
setting of signs or symptoms suggestive of myocardial
ischemia or MI (157,158). (Level of Evidence: A)
2. Obtaining an ECG is recommended in the setting of signs or
symptoms suggestive of myocardial ischemia, MI, or
arrhythmia (158,159). (Level of Evidence: B)
CLASS IIb
1. The usefulness of postoperative screening with troponin
levels in patients at high risk for perioperative MI but
without signs or symptoms suggestive of myocardial
ischemia or MI, is uncertain in the absence of established
risks and beneﬁts of a deﬁned management strategy
(160–166). (Level of Evidence: B)
2. The usefulness of postoperative screening with ECGs in pa-
tients at high risk for perioperative MI, but without signs or
symptoms suggestive of myocardial ischemia, MI, or
arrhythmia, is uncertain in the absence of establishedrisks and beneﬁts of a deﬁned management strategy
(158,159,167–169). (Level of Evidence: B)
CLASS III: NO BENEFIT
1. Routine postoperative screening with troponin levels in un-
selected patients without signs or symptoms suggestive
of myocardial ischemia or MI is not useful for guiding
perioperative management (157,158). (Level of Evidence: B)8. FUTURE RESEARCH DIRECTIONS
Current recommendations for perioperative cardiovascu-
lar evaluation and management for noncardiac surgery
are based largely on clinical experience and observational
studies, with few prospective RCTs. The GWC recom-
mends that future research on perioperative evaluation
and management span the spectrum from RCTs to
regional and national registries to focus on patient
outcomes.
Diagnostic cardiovascular testing continues to evolve,
with newer imaging modalities being developed, such as
coronary calcium scores, computed tomography angiog-
raphy, and cardiac magnetic resonance imaging. The
value of these modalities in preoperative screening is
uncertain and warrants further study.
The use of perioperative beta blockers in beta–blocker-
naïve patients undergoing noncardiac surgery remains
controversial because of uncertainty about the following
issues: 1) optimal duration for the initiation of beta
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2390blockers before elective noncardiac surgery; 2) optimal
dosing and titration protocol perioperatively to avoid
hemodynamic instability, including hypotension and
bradycardia; and 3) which elevated-risk patient subsets
would beneﬁt the most from initiation of perioperative
beta blocker. RCTs are needed to demonstrate when to
start beta-blocker therapy before noncardiac surgery, the
optimal type and dose, and titration protocol.
The evidence base for the predictive value of biomarkers
in the perioperative period has grown. However, the utility
of this information in inﬂuencing management and out-
come is unknown and is currently undergoing investigation.
The results of these investigations could lead to changes in
recommendations in the future.
To implement the recommendations of the current
perioperative CPGs effectively, a “perioperative team
approach” is needed. The perioperative team is intended
to engage clinicians with appropriate expertise; enhance
communication of the beneﬁts, risks, and alternatives;
and include the patient’s preferences, values, and goals.
Future research will also be needed to understand how
information on perioperative risk is incorporated into
patient decision making.PRESIDENTS AND STAFF
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2404APPENDIX 3. RELATED RECOMMENDATIONS FROM OTHER CPGSs From the 2011 CABG and PCI CPGsTABLE A Left Main CAD Revascularization RecommendationAnatomic Setting COR LOE References
UPLM or complex CAD
CABG and PCI I—Heart Team approach recommended C (170–172)
CABG and PCI IIa—Calculation of the STS and SYNTAX scores B (170,173–180)
UPLM*
CABG I B (181–187)
PCI IIa—For SIHD when both of the following are present: B (173,176,180,188–206)
2. Anatomic conditions associated with a low risk of PCI procedural
complications and a high likelihood of good long-term outcome
(e.g., a low SYNTAX score of #22, ostial, or trunk left main CAD)
3. Clinical characteristics that predict a signiﬁcantly increased risk
of adverse surgical outcomes (e.g., STS-predicted risk of
operative mortality $5%)
IIa—For UA/NSTEMI if not a CABG candidate B (173,194–197,202,203,205–207)
IIa—For STEMI when distal coronary ﬂow is TIMI ﬂow grade <3 and
PCI can be performed more rapidly and safely than CABG
C (191,208,209)
IIb—For SIHD when both of the following are present: B (173,176,180,188–206,210)
2. Anatomic conditions associated with a low-to-intermediate
risk of PCI procedural complications and intermediate-to-high
likelihood of good long-term outcome (e.g., low–intermediate
SYNTAX score of <33, bifurcation left main CAD)
3. Clinical characteristics that predict an increased risk of adverse
surgical outcomes (e.g., moderate–severe COPD, disability
from prior stroke, or prior cardiac surgery; STS-predicted
risk of operative mortality >2%)
III: Harm—For SIHD in patients (versus performing CABG)
with unfavorable anatomy for PCI and who are good
candidates for CABG
B (173,176,180–187,189,190)
3-vessel disease with or without proximal LAD artery disease*
CABG I B (183,187,211–214)
IIa—It is reasonable to choose CABG over PCI in patients
with complex 3-vessel CAD (e.g., SYNTAX >22)
who are good candidates for CABG
B (190,205,213,215,216)
PCI IIb—Of uncertain beneﬁt B (183,204,211,213,217)
2-vessel disease with proximal LAD artery disease*
CABG I B (183,187,211–214)
PCI IIb—Of uncertain beneﬁt B (183,211,213,217)
2-vessel disease without proximal LAD artery disease*
CABG IIa—With extensive ischemia B (218–221)
IIb—Of uncertain beneﬁt without extensive ischemia C (213)
PCI IIb—Of uncertain beneﬁt B (183,211,213,217)
1-vessel proximal LAD artery disease
CABG IIa—With LIMA for long-term beneﬁt B (187,213,222,223)
PCI IIb—Of uncertain beneﬁt B (183,211,213,217)
1-vessel disease without proximal LAD artery involvement
CABG III: Harm B (187,211,218,219,224–227)
PCI III: Harm B (187,211,218,219,224–227)
LV dysfunction
CABG IIa—EF 35% to 50% B (187,228–232)
CABG IIb—EF <35% without signiﬁcant left main CAD B (187,228–234)
PCI Insufﬁcient data N/A
Continued on the next page
TABLE A Continued
Anatomic Setting COR LOE References
Survivors of sudden cardiac death with presumed ischemia-mediated VT
CABG I B (235–237)
PCI I C (236)
No anatomic or physiological criteria for revascularization
CABG III: Harm B (187,211,218,219,224–227,238)
PCI III: Harm B (187,211,218,219,224–227,238)
*In patients with multivessel disease who also have diabetes mellitus, it is reasonable to choose CABG (with LIMA) over PCI (220,239–246) (Class IIa; LOE: B).
CABG indicates coronary artery bypass graft; CAD, coronary artery disease; COPD, chronic obstructive pulmonary disease; COR, Class of Recommendation; CPG, clinical practice
guideline; EF, ejection fraction; LAD, left anterior descending; LIMA, left internal mammary artery; LOE, Level of Evidence; LV, left ventricular; N/A, not applicable; PCI, percutaneous
coronary intervention; SIHD, stable ischemic heart disease; STEMI, ST-elevation myocardial infarction; STS, Society of Thoracic Surgeons; SYNTAX, Synergy Between Percutaneous
Coronary Intervention With TAXUS and Cardiac Surgery; TIMI, Thrombolysis In Myocardial Infarction; UA/NSTEMI, unstable angina/non–ST-elevation myocardial infarction; UPLM,
unprotected left main disease; and VT, ventricular tachycardia.
Reproduced from Levine et al. (27) and Hillis et al. (26).
TABLE B GDMT Recommendations for Beta Blockers From 2011 Secondary Prevention CPG
Beta Blockers CLASS I
1. Beta-blocker therapy should be used in all patients with LV systolic dysfunction (EF #40%) with HF or prior MI, unless contraindicated.
(Use should be limited to carvedilol, metoprolol succinate, or bisoprolol, which have been shown to reduce mortality.)
(247–249) (Level of Evidence: A)
2. Beta-blocker therapy should be started and continued for 3 years in all patients with normal LV function who have had MI or ACS
(250–252). (Level of Evidence: B)
CLASS IIa
1. It is reasonable to continue beta blockers >3 years as chronic therapy in all patients with normal LV function who have had MI or ACS
(250–252). (Level of Evidence: B)
2. It is reasonable to give beta-blocker therapy in patients with LV systolic dysfunction (EF #40%) without HF or prior MI.
(Level of Evidence: C)
ACS indicates acute coronary syndrome; CPG, clinical practice guideline; EF, ejection fraction; GDMT, guideline-directed medical therapy; HF, heart failure; LV, left ventricular; and MI,
myocardial infarction.
Reproduced from Smith Jr et al. (124).
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